An increased relative eosinophil count as a predictive dynamic biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors
Thoracic Cancer · 2024-01 · 15 (3) · 248-257
DOI: 10.1111/1759-7714.15191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 12.12.2023. Verfasst von Eiji Takeuchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Investigation, National Hospital Organization Kochi Hospital, Kochi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
An increased relative eosinophil count (REC) has potential as a predictive biomarker for a beneficial clinical response and outcome to cancer immunotherapies. Therefore, the present study investigated the impact of an increased posttreatment REC on the prognosis of non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).
Methods
We retrospectively reviewed all 151 patients diagnosed with NSCLC and treated with ICI monotherapy and blood test data between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University.
Results
A total of 151 patients with a mean age of 69 years were included. REC after 4 weeks of initial ICI monotherapy was higher than pretreatment REC in 87 patients but not in 64. REC after 4 weeks of the ICI treatment with and without an increased REC were 4.4 and 1.8%, respectively ( p < 0.001). Disease control rates (DCR) were significantly higher in patients with than in those without an increased REC (84% vs. 47%, p < 0.001). The median overall survival (OS) of lung cancer patients with or without an increased REC were 674 and 234 days, respectively. A Kaplan–Meier univariate analysis revealed a significant difference in OS between the two groups ( p < 0.001). A Cox proportional regression analysis identified an increased REC as an independent predictor of OS ( p = 0.003).
Conclusion
ICI‐treated NSCLC patients with an increased REC after 4 weeks of treatment had a better DCR and prognosis than the other patients examined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Investigation, National Hospital Organization Kochi Hospital, Kochi, Japan.
- Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
- Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
- Department of Pathology, National Hospital Organization Kochi Hospital, Kochi, Japan.
- Department of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
ORCID-Profile: Eiji Takeuchi, Hiroshi Nokihara, Yasuhiko Nishioka
Zitieren
APA
Takeuchi, E., Ogino, H., Kondo, K., Okano, Y., Ichihara, S., Kunishige, M., Kadota, N., Machida, H., Hatakeyama, N., Naruse, K., Nokihara, H., Shinohara, T., & Nishioka, Y. (2024). An increased relative eosinophil count as a predictive dynamic biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic Cancer, 15(3), 248-257. https://doi.org/10.1111/1759-7714.15191
Vancouver
Takeuchi E, Ogino H, Kondo K, Okano Y, Ichihara S, Kunishige M, et al. An increased relative eosinophil count as a predictive dynamic biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic Cancer. 2024;15(3):248-257. doi:10.1111/1759-7714.15191
BibTeX
@article{Takeuchi2024,
author = {Takeuchi, Eiji and Ogino, Hirokazu and Kondo, Kensuke and Okano, Yoshio and Ichihara, Seiya and Kunishige, Michihiro and Kadota, Naoki and Machida, Hisanori and Hatakeyama, Nobuo and Naruse, Keishi and Nokihara, Hiroshi and Shinohara, Tsutomu and Nishioka, Yasuhiko},
title = {An increased relative eosinophil count as a predictive dynamic biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors},
journal = {Thoracic Cancer},
year = {2024},
volume = {15},
number = {3},
pages = {248--257},
doi = {10.1111/1759-7714.15191}
}
EUVIMED